HOLBROOK, N.Y., May 29, 2013 /PRNewswire/ -- Northstar
Global Business Services, Inc. Symbol (OTCPink: MDIN), today
announced that after lengthy negotiations, it has closed a deal
with the owners, and inventors of one of the most exciting health
related patented processes in the US today. The patent, titled:
"Method of treating lactose intolerance using genetically
engineered bacteria," covers a process for the creation of a
product that when ingested, has been shown to have the potential of
completely alleviate the symptoms of lactose intolerance. The
product, developed in partnership with Celprogen, Inc. by it's
co-inventor, pharmacist Kenneth
Manzo, showed that when tested in laboratory rats, their
intolerance for lactose-based foods disappeared for up to three
months without taking additional doses of the product.
Lactose intolerance is the inability to digest milk and milk
products, and may cause symptoms ranging from mild to severe
abdominal pain, abdominal bloating, gas, diarrhea, and nausea. The
only treatment for this condition is to either avoid
lactose-containing foods and drinks altogether, or to take over the
counter pills before or immediately after the food is consumed.
Often lactose intolerant people may forget to take their pills, not
have any on them or accidentally consume something with lactose and
the result is illness and a severe disruption of everyday life.
This patent has the potential to make all of that discomfort and
disruption a thing of the past. A single dose of the product
produced using this patented method would basically change the
person's digestive system's behavior to that of someone without
lactose intolerance for up the three months at a time. This would
allow the individual to eat anything they please without taking a
single pill. Considering the difficulty and cost associated with
current over the counter treatments, Northstar feels the potential
of this product is almost limitless, and if executed properly could
put the company in a position of changing millions of lives for the
better.
Northstar CEO, Nick Chieco
commented, "This is nothing short of revolutionary for people who
suffer from lactose intolerance. We feel strongly that our product,
using this ingenious patented method, will be the only lactose
intolerance product anyone will want to take once it is
released. It's important for our shareholders to know that
our move in this direction, and our plans for the product as it
relates to Northstar are part of a much larger objective to move
from strictly non FDA approved supplements to the eventual FDA
approved over-the-counter medications space. What better way to
enter that space than with a unique, patented, and desperately
needed product such as this."
While the details of the deal remain yet to be disclosed, The
Company assures shareholders that neither precious capital, nor
free-trading equity were used to solidify the patent's use.
Instead, in order to avoid dilution or a shortfall of capital
needed to fund inventory, a deal was struck using restricted shares
with lock up periods in addition to a year as to avoid damage to
the tight share structure the company has worked so hard to create.
In the past couple months alone, Northstar has pulled over two
hundred million shares off the market through share buy backs,
negotiated purchases, and shares surrendered by management. Mr.
Chieco explained, "We knew we would need to issue restricted equity
to acquire additional patent licenses and properties such as this,
and that's one of the reasons we have been so aggressive in taking
shares off the market. Even if we didn't take so many shares off
the market, the number of shares we would have had outstanding due
to this deal would still not be excessive, for a company with our
revenues and market share. However, as we battle short selling and
other technical hurdles we felt we needed to trim down as much as
possible prior to doing a deal like this, and I believe we
definitely achieved that goal. " Mr. Chieco also wants to let
shareholders know that he will continue using the strategy to take
additional shares off the market moving forward, and he is
extremely confident that as the end of the quarter nears, Northstar
is ever closer to reaching it's goal of delivering audited
financials and re-listing on the OTCBB.
About Northstar
Northstar Global Business Services is dedicated to producing the
best alternative healthcare products. The most popular products
Northstar's sells are Snorenz©, a patented spray for snoring
relief, Stem-Intense, a unique stem cell replacement therapy
supplement, and Health-Enrich for pets, an exciting new supplement
that promotes pet health and can help relieve many problems
experienced by aging pets. Most of the company's products use a
proprietary or patented formula, spray delivery system, or
ingredients, and have received very positive consumer reviews all
over the world, selling millions of units from 1996 to the present.
For more information please call Jennifer at 877-571-4387 or email
investor@northstarbb.com
DISCLAIMER
This Press Release may contain certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. The Company has tried, whenever possible, to identify
these forward-looking statements using words such as "anticipates,"
"believes," "estimates," "expects," "plans," "intends," "potential"
and similar expressions. These statements reflect the Company's
current beliefs and are based upon information currently available
to it. Accordingly, such forward-looking statements involve known
and unknown risks, uncertainties and other factors which could
cause the Company's actual results, performance or achievements to
differ materially from those expressed in or implied by such
statements. The Company undertakes no obligation to update or
advise in the event of any change, addition or alteration to the
information catered in this Press Release including such
forward-looking statements.
SOURCE Northstar Global Business Services, Inc.